• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    1/17/24 12:31:12 PM ET
    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 26.1% to $3.33 during Wednesday's regular session. The company's market cap stands at $20.2 million.
    • MAIA Biotechnology (AMEX:MAIA) shares rose 26.02% to $1.55. The company's market cap stands at $26.2 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 24.42% to $0.16.
    • Anitra (AMEX:AZTR) shares moved upwards by 22.64% to $1.95. The market value of their outstanding shares is at $23.5 million.
    • Evolus (NASDAQ:EOLS) shares rose 17.74% to $12.28. The market value of their outstanding shares is at $709.3 million.
    • Jasper Therapeutics (NASDAQ:JSPR) stock increased by 16.42% to $10.42. The market value of their outstanding shares is at $116.2 million.

    Losers

    • Adagene (NASDAQ:ADAG) stock declined by 40.5% to $2.25 during Wednesday's regular session. The market value of their outstanding shares is at $98.6 million.
    • Estrella Immunopharma (NASDAQ:ESLA) stock declined by 18.71% to $1.04. The market value of their outstanding shares is at $36.6 million.
    • NexImmune (NASDAQ:NEXI) stock declined by 18.13% to $8.31. The company's market cap stands at $8.7 million.
    • Jin Medical International (NASDAQ:ZJYL) shares fell 17.16% to $91.11. The company's market cap stands at $713.1 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock declined by 16.85% to $3.95. The market value of their outstanding shares is at $54.3 million.
    • Cano Health (NYSE:CANO) shares declined by 15.44% to $2.52. The company's market cap stands at $7.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $ADAG
    $AZTR
    $BFRG

    CompanyDatePrice TargetRatingAnalyst
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    Evolus Inc.
    $EOLS
    8/6/2025Buy → Hold
    Needham
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$4.00Outperform → Market Perform
    BMO Capital Markets
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$5.00Outperform → Sector Perform
    RBC Capital Mkts
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Overweight → Neutral
    Cantor Fitzgerald
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    SEC Filings

    View All

    SEC Form 10-K filed by Bullfrog AI Holdings Inc.

    10-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    3/19/26 4:45:34 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.

    6-K - Jin Medical International Ltd. (0001837821) (Filer)

    3/17/26 4:30:16 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Azitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/13/26 5:26:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

    SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year's AACR Meeting, taking place April 17-22 in San Diego, CA. The following abstracts have been selected for presentation at AACR 2026: Title: Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO doublet in combination with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancerSession Title: Phase I Clinical Trials in Pr

    3/17/26 4:35:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

    BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As previously reported, on Octobe

    3/13/26 5:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Avelar Rui

    4 - Evolus, Inc. (0001570562) (Issuer)

    3/18/26 8:00:32 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moatazedi David

    4 - Evolus, Inc. (0001570562) (Issuer)

    3/18/26 8:00:35 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Adagene Inc.

    3 - Adagene Inc. (0001818838) (Issuer)

    3/18/26 9:05:24 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Adagene with a new price target

    Leerink Partners initiated coverage of Adagene with a rating of Outperform and set a new price target of $7.00

    8/6/25 7:24:59 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chaouki Steven M bought $49,999 worth of shares (40,849 units at $1.22), increasing direct ownership by 37% to 151,873 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:16:48 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

    Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company's Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half 2026 Net Revenue Guidance of $327 Million to $337 Million,

    3/3/26 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a

    2/17/26 8:00:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian

    9/8/25 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADAG
    $AZTR
    $BFRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:50:28 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:00:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care